ERBB2 and breast carcinoma: Importantly, it was suggested that combining trastuzumab with the PAI1 inhibitor aleplasinin effectively reduces PAI1 expression, presenting a promising therapeutic strategy to overcome trastuzumab resistance in HER2-positive breast cancer.